Quick Answer
Raphael Pharmaceutical Inc. reported Net Income of -$1.28 million for fiscal year 2025.
Raphael Pharmaceutical Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$1.28M +15.8% |
-$1.52M -13.0% |
-$1.34M +60.0% |
-$3.36M -106.8% |
-$1.62M -126.2% |
-$718.0K |
| Diluted EPS | $0.07 -12.5% |
$0.08 +0.0% |
$0.08 -65.2% |
$0.23 +64.3% |
$0.14 | — |
| Total Assets | $53.0K +96.3% |
$27.0K -88.7% |
$239.0K -28.2% |
$333.0K -21.1% |
$422.0K +30.7% |
$323.0K |
| Cash and Equivalents | — | $19.0K -91.7% |
$230.0K -20.1% |
$288.0K +88.2% |
$153.0K +61.1% |
$95.0K |
| Stockholders Equity | -$1.43M -93.1% |
-$742.0K -793.5% |
$107.0K +0.9% |
$106.0K -17.2% |
$128.0K +397.7% |
-$43.0K -120.7% |
| R&D Expense | $631.0K -18.7% |
$776.0K +36.4% |
$569.0K -51.7% |
$1.18M +51.8% |
$776.0K +68.3% |
$461.0K |
| Operating Income | -$1.25M +17.5% |
-$1.51M -13.3% |
-$1.33M +59.8% |
-$3.32M -103.6% |
-$1.63M -130.7% |
-$706.0K |
| Shares Outstanding | 20.18M +7.9% |
18.70M +1.1% |
18.50M +18.4% |
15.62M +15623940.0% |
100 -100.0% |
9.46M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$255.0K | +21.8% | +20.8% |
| Diluted EPS | September 30, 2025 | $0.01 | +0.0% | -50.0% |
| Total Assets | September 30, 2025 | $7.0K | -86.3% | -76.7% |
| Cash and Equivalents | June 30, 2025 | $20.0K | -83.3% | -60.0% |
| Stockholders Equity | September 30, 2025 | -$1.26M | -105.2% | -20.6% |
| R&D Expense | September 30, 2025 | $73.0K | -54.9% | -48.2% |
| Operating Income | September 30, 2025 | -$251.0K | +21.3% | +20.3% |
| Shares Outstanding | September 30, 2025 | 19.63M | +4.9% | +0.0% |
- Raphael Pharmaceutical Inc. reported Net Income of -$1.28 million for fiscal year 2025.
- Raphael Pharmaceutical Inc. showed an increase of +15.8% in Net Income compared to the prior fiscal year.
- Raphael Pharmaceutical Inc. reported Diluted EPS of $0.07 per share for fiscal year 2025.
- Raphael Pharmaceutical Inc. showed a decrease of -12.5% in Diluted EPS compared to the prior fiscal year.
- Raphael Pharmaceutical Inc. reported Total Assets of $53.0 thousand for fiscal year 2025.
- Raphael Pharmaceutical Inc. showed an increase of +96.3% in Total Assets compared to the prior fiscal year.
- Raphael Pharmaceutical Inc. reported Cash and Equivalents of $19.0 thousand for fiscal year 2024.
- Raphael Pharmaceutical Inc. showed a decrease of -91.7% in Cash and Equivalents compared to the prior fiscal year.
- Raphael Pharmaceutical Inc. reported Stockholders Equity of -$1.43 million for fiscal year 2025.
- Raphael Pharmaceutical Inc. showed a decrease of -93.1% in Stockholders Equity compared to the prior fiscal year.
- Raphael Pharmaceutical Inc. reported R&D Expense of $631.0 thousand for fiscal year 2025.
- Raphael Pharmaceutical Inc. showed a decrease of -18.7% in R&D Expense compared to the prior fiscal year.
- Raphael Pharmaceutical Inc. reported Operating Income of -$1.25 million for fiscal year 2025.
- Raphael Pharmaceutical Inc. showed an increase of +17.5% in Operating Income compared to the prior fiscal year.
- Raphael Pharmaceutical Inc. reported Shares Outstanding of 20.18 million shares for fiscal year 2025.
- Raphael Pharmaceutical Inc. showed an increase of +7.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: